502O_PR - Optimal first line systemic therapy in patients (pts) with metastatic angiosarcoma: A report from the Asian Sarcoma Consortium

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Sarcoma
Topics Cytotoxic agents
Soft Tissue Sarcomas
Presenter Tom Chen
Citation Annals of Oncology (2016) 27 (suppl_9): ix163-ix168. 10.1093/annonc/mdw597
Authors T.W. Chen1, A. Pang2, M.E. Puhaindran3, M.M. Maw4, H.H. Loong5, V. Sriuranpong6, C. Chang7, S. Teo2, S. Mingmalairak6, T. Hirose8, M. Endo8, A. Kawai8, M. Farid9, S.H. Tan10, W.L. Goh9, R. Quek9, J.C. Chan11, A.K.C. Leung11, R. Ngan11
  • 1Department Of Oncology, National Taiwan University Hospital, 100 - Taipei/TW
  • 2Department Of Haematology-oncology, National University Cancer Institute, Singapore, 119074 - Singapore/SG
  • 3Department Of Hand And Reconstructive Microsurgery, National University Hospital, 119228 - Singapore/SG
  • 4Medical Oncology Unit, University of Medicine 1, Yangon, 11131 - Yangon/MM
  • 5Department Of Clinical Oncology, The Chinese University of Hong Kong, NA - Shatin/HK
  • 6Division Of Medical Oncology, Department Of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, 10330 - Bangkok/TH
  • 7Department Of Cancer Administration And Coordination Center, National Taiwan University Hospital, 100 - Taipei/TW
  • 8Division Of Musculoskeletal Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 9Division Of Medical Oncology, National Cancer Center, 169610 - Singapore/SG
  • 10Division Of Clinical Trials And Epidemiological Sciences, National Cancer Center, 169610 - Singapore/SG
  • 11Department Of Clinical Oncology, Queen Elizabeth Hospital, NA - Hong Kong/CN



Metastatic/unresectable angiosarcoma (AS) is a disease with poor prognosis. Median survival is generally less than 12 mths. Single agent taxane or anthracycline are commonly used agents. However optimal 1st line systemic treatment remains to be defined.


We undertook a retrospective chart review of AS pts seen in 8 sarcoma academic centres across Asia. Pts with complete clinical, treatment and follow up data were enrolled.


271 metastatic/unresectable AS pts were included into this study. Median age was 64 yrs. 64% of pts presented with metastatic/unresectable disease at time of initial diagnosis while 36% developed metachronous metastatic disease at a median of 7.6 mths following initial diagnosis. Primary origin of tumor was from a cutaneous site in 55% vs a visceral site in 45% of pts; the most common visceral site being the liver. 52% of these pts received systemic chemotherapy, of whom 55%, 25% and 20% of these pts received 1 line, 2 lines and >3 lines of chemotherapy respectively. Of pts who received systemic chemotherapy, the most common 1st line regimen used was paclitaxel in 47% and liposomal doxorubicin in 19%. At a median follow-up of 7.2 mths after diagnosis of metastatic/unresectable disease, overall survival (OS) was 8.3 mths, 11.5 mths in those who received at least 1 line of palliative chemotherapy vs 4.4 mths (p 


This study confirms the poor prognosis of pts with metastatic/unresectable angiosarcoma AS. First line treatment with single agent taxane or anthracycline appears comparable.

Clinical trial indentification

Legal entity responsible for the study

National Cancer Centre Singapore




V. Sriuranpong: Corporate sponsored research: Novartis, MSD, Astra Zeneca, Roche, Lilly, Sanofi, Pfizer, BMS. R. Quek: Grants/research support: Novartis, Pfizer, Janssen, Bayer and Eisai Honoraria or consultation fees: Novartis, Bayer, BMS, Merck, Roche and Eisai Participation in a company sponsored speaker’s bureau: Novartis, Bayer, Merck and Eisai. All other authors have declared no conflicts of interest.